Table S7 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

Wang, Peng; Sun, Xin; He, Xueting; Kang, Di; Liu, Xiaoyu; Liu, Dan; Li, Amin; Yang, Guiqun; Lin, Yiwei; Li, Sujing; Wang, Yinxiang; Wang, Yanping

doi:10.1158/2767-9764.29071248

Table S7 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

journal contribution

posted on 2025-05-15, 12:17 authored by Peng Wang, Xin Sun, Xueting He, Di Kang, Xiaoyu Liu, Dan Liu, Amin Li, Guiqun Yang, Yiwei Lin, Sujing Li, Yinxiang Wang, Yanping Wang

Table S7 shows IC50 values in p-ERK inhibition assays and cell viability assays.

History

ARTICLE ABSTRACT

Glecirasib potently and selectively inhibits KRAS G12C and reduces ERK and AKT phosphorylation in KRAS G12C–mutant cancer cells, further inducing cell-cycle arrest and apoptosis. Glecirasib monotherapy leads to tumor regression in KRAS G12C–mutant animal models and shows synergistic effects with cetuximab or JAB-3312 (sitneprotafib).

Usage metrics

Keywords

Cellular Responses To Anticancer Drugs Drug Mechanisms Pharmacology Cellular pharmacology Pharmacokinetics and pharmacodynamics Small Molecule Agents

Licence

CC BY

Table S7 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports